$22 Million Joint Venture To Purse Neurochemical Reset For Addiction

A joint venture has been set up by ATAI Life Sciences and DemeRX to develop a one and done treatment that will work to give people suffering from addiction a neurochemical reset of sorts using a drug derived from a Western African plant. 

The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant ...

Continue Reading →

MindMed, a Silicon Valley Startup, Tests Psychedelics to Treat Addiction

Psychedelic medicine is hot right now—or regulatory agencies seem to be warming up to the idea, at least. Over the last few years, the FDA has begun to approve (and even fast-track) clinical trials examining the impact of substances like ketamine, psilocybin, and MDMA on mental health issues like post-traumatic stress disorder and major depressive disorder. In addition to contributing to the growing ...

Continue Reading →
Page 1 of 8 12345...»